REGEND 001
Alternative Names: REGEND-001Latest Information Update: 17 Oct 2023
At a glance
- Originator Regend Therapeutics
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis
- Preclinical Interstitial lung diseases
Most Recent Events
- 07 Oct 2023 Phase-II clinical trials in Idiopathic pulmonary fibrosis in China (Parenteral) (NCT06081621)
- 09 Jun 2023 Regend Therapeutics completes a phase I/II clinical trial in Idiopathic pulmonary fibrosis (In adults, In the elderly) in China (Parenteral) (NCT05657184)
- 15 Dec 2022 Regend Therapeutics has patent pending for autologous bronchial basal cell preparation process in the USA, Europe and China .